What is Invitae?
Headquartered in San Francisco, Invitae operates at the intersection of biotechnology and clinical diagnostics. The company specializes in processing DNA-containing samples derived from in-home test kits, providing comprehensive genetic variation analysis. By generating actionable test reports for clinicians and patients, Invitae facilitates precision medicine, enabling more informed treatment planning and monitoring. Its business model relies on high-throughput genomic intelligence, positioning it as a critical service provider in the evolving landscape of personalized healthcare and molecular diagnostics.
How much funding has Invitae raised?
Invitae has raised a total of $1.2B across 11 funding rounds:
Series F
$120M
Stock Offering
$116.8M
Share Placement
$73.5M
Debt
$40M
Stock Offering
$53.5M
Stock Offering
$196.7M
Debt
$291.2M
Stock Offering
$184M
Share Placement
$30M
Series F (2014): $120M supported by Genomic Health, Deerfield Management, Randy Scott, Redmile Group, Perceptive Advisors, Thomas McNerney & Partners, Wellington Management, Decheng Capital, The Broe Group, Casdin Capital, Genesys Capital, OrbiMed, and Rock Springs Capital
Stock Issuance/Offering (2015): $116.8M featuring Undisclosed
Share Placement (2017): $73.5M backed by Undisclosed
Debt (2018): $40M with participation from Oxford Finance
Stock Issuance/Offering (2018): $53.5M led by Undisclosed
Stock Issuance/Offering (2019): $196.7M supported by Undisclosed
Debt (2019): $291.2M featuring Undisclosed
Stock Issuance/Offering (2020): $184M backed by Undisclosed
Share Placement (2023): $30M, investors not publicly disclosed
Key Investors in Invitae
Casdin Capital
Casdin Capital is a specialized investment firm focused on the life sciences sector, providing long-term capital to pioneers in diagnostics and molecular information.
OrbiMed
OrbiMed is a global healthcare-focused investment firm that manages capital across biopharmaceuticals, medical devices, and diagnostics to support innovation at all development stages.
Genesys Capital
Genesys Capital is a Toronto-based venture capital firm dedicated to early-stage life sciences and healthcare companies, fostering medical innovation across North America.
What's next for Invitae?
Following the latest capital infusion, Invitae is well-positioned to accelerate its strategic initiatives. The company is expected to focus on enhancing its diagnostic throughput and refining its proprietary genetic analysis platforms. As the demand for accessible, high-quality genetic testing continues to rise, Invitae will likely leverage its recent financing to deepen its integration into clinical workflows, potentially exploring new therapeutic areas and expanding its footprint in the competitive molecular screening market. The firm remains focused on translating complex genomic data into clinical utility, a core pillar of its long-term growth strategy.
See full Invitae company page
